Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging

17-01-2024 | Positron Emission Tomography | Review

Imaging Procedure and Clinical Studies of [18F]FP-CIT PET

Authors: Changhwan Sung, Seung Jun Oh, Jae Seung Kim

Published in: Nuclear Medicine and Molecular Imaging

Login to get access

Abstract

N-3-[18F]fluoropropyl-2β-carbomethoxy-3β-4-iodophenyl nortropane ([18F]FP-CIT) is a radiopharmaceutical for dopamine transporter (DAT) imaging using positron emission tomography (PET) to detect dopaminergic neuronal degeneration in patients with parkinsonian syndrome. [18F]FP-CIT was granted approval by the Ministry of Food and Drug Safety in 2008 as the inaugural radiopharmaceutical for PET imaging, and it has found extensive utilization across numerous institutions in Korea. This review article presents an imaging procedure for [18F]FP-CIT PET to aid nuclear medicine physicians in clinical practice and systematically reviews the clinical studies associated with [18F]FP-CIT PET.
Literature
1.
Coenen HH, Dutschka K, Müller SP, Geworski L, Farahati J, Reiners C. N.c.a. radiosynthesis of [123,124I]beta-CIT, plasma analysis and pharmacokinetic studies with SPECT and PET. Nucl Med Biol. 1995;22:977–84.PubMedCrossRef
2.
Kung MP, Stevenson DA, Plössl K, Meegalla SK, Beckwith A, Essman WD, et al. [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372–80.PubMed
3.
Kim JS, Oh SJ, Moon DH. Molecular imaging in neurodegenerative diseases. J Korean Med Assoc. 2009;52:151–67.CrossRef
4.
Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L. [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997;24:621–7.PubMedCrossRef
5.
Sihver W, Drewes B, Schulze A, Olsson RA, Coenen HH. Evaluation of novel tropane analogues in comparison with the binding characteristics of [18F]FP-CIT and [131I]beta-CIT. Nucl Med Biol. 2007;34:211–9.PubMedCrossRef
6.
Kong Y, Zhang C, Liu K, Wagle Shukla A, Sun B, Guan Y. Imaging of dopamine transporters in Parkinson disease: a meta-analysis of (18) F/(123) I-FP-CIT studies. Ann Clin Transl Neurol. 2020;7:1524–34.PubMedPubMedCentralCrossRef
7.
Lee I, Kim JS, Park JY, Byun BH, Park SY, Choi JH, et al. Head-to-head comparison of (18) F-FP-CIT and (123) I-FP-CIT for dopamine transporter imaging in patients with Parkinson’s disease: A preliminary study. Synapse. 2018;72: e22032.PubMedCrossRef
8.
9.
10.
Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424–38.PubMedCrossRef
11.
Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–6.PubMedCrossRef
12.
Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359–66.PubMed
13.
Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, et al. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol. 1996;23:999–1004.PubMedCrossRef
14.
Lee SJ, Oh SJ, Chi DY, Kang SH, Kil HS, Kim JS, et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nucl Med Biol. 2007;34:345–51.PubMedCrossRef
15.
Lee SJ, Oh SJ, Moon WY, Choi MS, Kim JS, Chi DY, et al. New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: a 1.5-year production report. Nucl Med Biol. 2011;38:593–7.PubMedCrossRef
16.
Lee SJ, Oh SJ, Chi DY, Jin-Sook R, Dae-Hyuk M. High yielding [18F]Fluorination method by fine control of the base. Bull Korean Chem Soc. 2012;33:2177–80.CrossRef
17.
Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–30.PubMed
18.
Yaqub M, Boellaard R, van Berckel BN, Ponsen MM, Lubberink M, Windhorst AD, et al. Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography. J Cereb Blood Flow Metab. 2007;27:1397–406.PubMedCrossRef
19.
Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med. 1999;40:753–61.PubMed
20.
Oh JK, Yoo ID, Seo YY, Chung YA, Yoo Ie R, Kim SH, et al. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson’s Disease. Nucl Med Mol Imaging. 2011;45:255–60.PubMedPubMedCentralCrossRef
21.
Jin S, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clin Nucl Med. 2017;42:e80–7.PubMedCrossRef
22.
Alberts I, Sachpekidis C, Prenosil G, Viscione M, Bohn KP, Mingels C, et al. Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [(18)F]-FDG PET/CT. Ann Nucl Med. 2021;35:485–92.PubMedPubMedCentralCrossRef
23.
Gur RC, Ragland JD, Reivich M, Greenberg JH, Alavi A, Gur RE. Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state. Cereb Cortex. 2009;19:375–82.PubMedCrossRef
24.
Hong CM, Ryu HS, Ahn BC. Early perfusion and dopamine transporter imaging using (18)F-FP-CIT PET/CT in patients with parkinsonism. Am J Nucl Med Mol Imaging. 2018;8:360–72.PubMedPubMedCentral
25.
Jin S, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. Nucl Med Mol Imaging. 2013;47:44–51.PubMedCrossRef
26.
Chun K, Kong E, Cho I. Comparison of perfusion 18F-FP-CIT PET and 99mTc-ECD SPECT in parkinsonian disorders. Medicine (Baltimore). 2021;100: e27019.PubMedCrossRef
27.
Oh M, Lee N, Kim C, Son HJ, Sung C, Oh SJ, et al. Diagnostic accuracy of dual-phase (18)F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Sci Rep. 2021;11:14992.PubMedPubMedCentralCrossRef
28.
Peng S, Tang C, Schindlbeck K, Rydzinski Y, Dhawan V, Spetsieris PG, et al. Dynamic (18)F-FPCIT PET: quantification of Parkinson’s disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session. J Nucl Med. 2021;62:1775–82.PubMedPubMedCentralCrossRef
29.
An YS, Yoon JH, Son SJ, Hong CH, Lee SJ, Yoon JK. Early-phase (18)F-FP-CIT and (18)F-flutemetamol PET were significantly correlated. Sci Rep. 2021;11:12297.PubMedPubMedCentralCrossRef
30.
Lee JY, Seo SH, Kim YK, Yoo HB, Kim YE, Song IC, et al. Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. 2014;85:23–30.PubMedCrossRef
31.
Hong CM, Kim DH, Ahn BC, Seo JG, Ryu HS. Relationship between Apathy and Subjective Poor Night-time Sleep in de novo. Untreated Parkinson’s Disease J Integr Neurosci. 2022;21:74.PubMed
32.
Kim A, Kim HJ, Jeon B. Importance of proper window setting in visual assessment of dopamine transporter imaging: A case of early-onset parkinsonism related to Park2 gene mutation. Neurology Asia. 2016;21:187–9.
33.
Knudsen K, Fedorova TD, Horsager J, Andersen KB, Skjærbæk C, Berg D, et al. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes. J Parkinsons Dis. 2021;11:1677–87.PubMedCrossRef
34.
Horsager J, Knudsen K, Sommerauer M. Clinical and imaging evidence of brain-first and body-first Parkinson’s disease. Neurobiol Dis. 2022;164: 105626.PubMedCrossRef
35.
Wüllner U, Borghammer P, Choe CU, Csoti I, Falkenburger B, Gasser T, et al. The heterogeneity of Parkinson’s disease. J Neural Transm (Vienna). 2023;130:827–38.PubMedCrossRef
36.
Borghammer P. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. J Parkinsons Dis. 2021;11:455–74.PubMedCentralCrossRef
37.
Sung C, Lee JH, Oh JS, Oh M, Lee SJ, Oh SJ, et al. Longitudinal Decline of Striatal Subregional [(18)F]FP-CIT Uptake in Parkinson’s Disease. Nucl Med Mol Imaging. 2017;51:304–13.PubMedPubMedCentralCrossRef
38.
Martínez-Valle Torres MD, Ortega Lozano SJ, Gómez Heredia MJ, Amrani Raissouni T, Ramos Moreno E, Moya Espinosa P, et al. Longitudinal evaluation using FP-CIT in patients with parkinsonism. Neurología (English Edition). 2014;29:327–33.CrossRef
39.
Kim YI, Im HJ, Paeng JC, Lee JS, Eo JS, Kim DH, et al. Validation of Simple Quantification Methods for (18)F-FP-CIT PET Using Automatic Delineation of Volumes of Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting. Nucl Med Mol Imaging. 2012;46:254–60.PubMedPubMedCentralCrossRef
40.
Jeong E, Oh SY, Pahk K, Lee CN, Park KW, Lee JS, et al. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson’s Disease. Nucl Med Mol Imaging. 2013;47:73–80.PubMedPubMedCentralCrossRef
41.
Kim JS, Cho H, Choi JY, Lee SH, Ryu YH, Lyoo CH, et al. Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. PLoS ONE. 2015;10: e0132585.PubMedPubMedCentralCrossRef
42.
Jeong YJ, Son HJ, Yoon HJ, Kang DY. Functional volumetric analysis of striatum using F-18 FP-CIT PET in patients with idiopathic Parkinson’s disease and normal subjects. Ann Nucl Med. 2016;30:572–8.PubMedCrossRef
43.
Bae S, Choi H, Whi W, Paeng JC, Cheon GJ, Kang KW, et al. Spatial Normalization Using Early-Phase [(18)F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding. Nucl Med Mol Imaging. 2020;54:305–14.PubMedPubMedCentralCrossRef
44.
Son HJ, Oh JS, Oh M, Lee SJ, Oh SJ, Chung SJ, et al. Test-retest reproducibility of dopamine transporter density measured with [(18)F]FP-CIT PET in patients with essential tremor and Parkinson’s disease. Ann Nucl Med. 2021;35:299–306.PubMedCrossRef
45.
Robeson W, Dhawan V, Belakhlef A, Ma Y, Pillai V, Chaly T, et al. Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med. 2003;44:961–6.PubMed
46.
Booij J, Busemann Sokole E, Stabin MG, Janssen AG, de Bruin K, van Royen EA. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25:24–30.PubMedCrossRef
47.
Robeson W, Dhawan V, Ma Y, Bjelke D, Margouleff C, Chaly T, et al. Radiation absorbed dose to the basal ganglia from dopamine transporter radioligand 18F-FPCIT. Biomed Res Int. 2014;2014: 498072.PubMedPubMedCentralCrossRef
48.
49.
Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [18F]FPCIT binding in early stage Parkinson’s disease: a PET study. Synapse. 2002;45:125–33.PubMedCrossRef
50.
Park E, Hwang YM, Lee CN, Kim S, Oh SY, Kim YC, et al. Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [(18)F]FP-CIT PET/CT. Nucl Med Mol Imaging. 2014;48:106–13.PubMedCrossRef
51.
You S, Kim MJ, Kim SR, Kim MJ, Oh M, Kim JS, et al. Clinical features and nigrostriatal dysfunction in patients with combined postural and resting tremors. Parkinsonism Relat Disord. 2013;19:1118–22.PubMedCrossRef
52.
Ahn JH, Kim LJ, Kim EY, Park JJ, Yoon BN. Dramatic unilateral decrease in uptake via the dopamine transporter: imaging in a patient with hemiparkinsonism following the lacunar stroke in substantia nigra. Neurol Asia. 2019;24:75–8.
53.
Kim C, Kim DY, Hong IK. Vascular Parkinsonism by Infarctions at Different Locations on 18F-FP-CIT PET/CT. Clin Nucl Med. 2019;44:e627–8.PubMedCrossRef
54.
Cheon M, Lee KH. Focal increased 18F FP-CIT uptake in a recent ischemic lesion in the frontal lobe. Clin Nucl Med. 2015;40:e137–9.PubMedCrossRef
55.
Lee YH, Lee S, Chung SJ, Yoo HS, Jung JH, Baik K, et al. The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism. Parkinsonism Relat Disord. 2021;82:1–6.PubMedCrossRef
56.
Shin S, Jun S, Nam HY. Effect of white matter hyperintensity on dopamine transporter availability of striatum measured by F-18 FP-CIT PET. Jpn J Radiol. 2021;39:1097–102.PubMedCrossRef
57.
Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53:399–406.PubMedCrossRef
58.
Kim HW, Kim JS, Oh M, Oh JS, Lee SJ, Oh SJ, et al. Different loss of dopamine transporter according to subtype of multiple system atrophy. Eur J Nucl Med Mol Imaging. 2016;43:517–25.PubMedCrossRef
59.
Han S, Oh M, Oh JS, Lee SJ, Oh SJ, Chung SJ, et al. Subregional Pattern of Striatal Dopamine Transporter Loss on 18F FP-CIT Positron Emission Tomography in Patients With Pure Akinesia With Gait Freezing. JAMA Neurol. 2016;73:1477–84.PubMedCrossRef
60.
Park HK, Kim JS, Im KC, Oh SJ, Kim MJ, Lee JH, et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses. Mov Disord. 2009;24:237–45.PubMedCrossRef
61.
Yoo HS, Chung SJ, Kim SJ, Oh JS, Kim JS, Ye BS, et al. The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. Eur J Nucl Med Mol Imaging. 2018;45:1585–95.PubMedCrossRef
62.
Yoo J, Cheon M. Differential diagnosis of patients with atypical Parkinsonian syndrome using (18)F-FDG and (18)F-FP CIT PET: A report of five cases. Radiol Case Rep. 2022;17:2765–70.PubMedPubMedCentralCrossRef
63.
Cheon M, Kim SM, Ha SW, Kang MJ, Yang HE, Yoo J. Diagnostic performance for differential diagnosis of atypical parkinsonian syndromes from parkinson’s disease using quantitative indices of (18)F-FP-CIT PET/CT. Diagnostics (Basel). 2022;12:1402.PubMedCrossRef
64.
Min JH, Park DG, Yoon JH, An YS. Dual-Phase 18F-FP-CIT PET in Corticobasal Syndrome. Clin Nucl Med. 2019;44:e49–50.PubMedCrossRef
65.
Park DG, An YS, Yoon JH. Serial 18F-FP-CIT and FDG PET in Fulminant Corticobasal Syndrome. Clin Nucl Med. 2021;46:754–5.PubMedCrossRef
66.
Chung SJ, Lee YH, Yoo HS, Sohn YH, Ye BS, Cha J, et al. Distinct FP-CIT PET patterns of Alzheimer’s disease with parkinsonism and dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2019;46:1652–60.PubMedCrossRef
67.
Lee H, Sung YH, Hwang KH. Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation of Essential Tremor and Parkinsonism. Curr Med Imaging. 2023;19:1041–51.PubMed
68.
Kang K, Choi D, Lee HW. Unusual idiopathic normal pressure hydrocephalus patient with marked asymmetric and upper body parkinsonism. Ann Indian Acad Neurol. 2016;19:245–8.PubMedPubMedCentralCrossRef
69.
Lee JY, Park SB, Lee M, Ju H, Im K, Kwon KY. Detailed visual assessment of striatal dopaminergic depletion in patients with idiopathic normal pressure hydrocephalus: unremarkable or not? BMC Neurol. 2020;20:277.PubMedPubMedCentralCrossRef
70.
Kim S, Song IU, Chung YA, Choi EK, Oh JK. Brain MRI, Tc-99m HMPAO SPECT and F-18 FP-CIT PET/CT Findings in a Patient with Wilson Disease: A Case Report. Nucl Med Mol Imaging. 2014;48:303–5.PubMedPubMedCentralCrossRef
71.
Shin S, Kim K, Pak K, Nam HY, Kim SJ, Kim IJ. Effects of Maturation on Striatal Dopamine Transporter Availability in Rats. Nuklearmedizin. 2019;58:395–400.PubMedCrossRef
72.
Lee CS, Kim SJ, Oh SJ, Kim HO, Yun SC, Doudet D, et al. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson’s disease. Ann Nucl Med. 2014;28:874–9.PubMedCrossRef
73.
Asanuma K, Dhawan V, Carbon M, Eidelberg D. Assessment of disease progression in parkinsonism. J Neurol. 2004;251(Suppl 7):vII4-8.PubMed
74.
Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH. Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson’s Disease: Impact on Clinical Features. J Mov Disord. 2019;12:113–9.PubMedPubMedCentralCrossRef
75.
Chung SJ, Yoo HS, Lee YH, Sohn YH, Ye BS, Cha J, et al. Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. Parkinsonism Relat Disord. 2020;81:140–3.PubMedCrossRef
76.
Lee DY, Oh M, Kim SJ, Oh JS, Chung SJ, Kim JS. Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease. Clin Nucl Med. 2019;44:855–9.PubMedCrossRef
77.
Pak K, Seo S, Lee MJ, Kim K, Suh S, Im HJ, et al. Striatal DAT availability does not change after supraphysiological glucose loading dose in humans. Endocr Connect. 2021;10:1266–72.PubMedPubMedCentralCrossRef
78.
Pak K, Seo S, Lee MJ, Kim K, Suh S, Lee J, et al. Hedonic Rating of Sucrose Is Sub-Regionally Associated with Striatal Dopamine Transporter in Humans. Neuroendocrinology. 2022;112:338–44.PubMedCrossRef
79.
Lee Y, Oh JS, Chung SJ, Chung SJ, Kim SJ, Nam CM, et al. Does smoking impact dopamine neuronal loss in de novo Parkinson disease? Ann Neurol. 2017;82:850–4.PubMedCrossRef
80.
81.
Kim SY, Choi HG, Kim YH, Kwon MJ, Kim JH, Lee HS, et al. Longitudinal study of the inverse relationship between Parkinson’s disease and cancer in Korea. NPJ Parkinsons Dis. 2023;9:116.PubMedPubMedCentralCrossRef
82.
Sunwoo MK, Hong JY, Lee JJ, Lee PH, Sohn YH. Does education modify motor compensation in Parkinson’s disease? J Neurol Sci. 2016;362:118–20.PubMedCrossRef
83.
Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.PubMedPubMedCentralCrossRef
84.
Chahid Y, Sheikh ZH, Mitropoulos M, Booij J. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [(123)I]I-FP-CIT SPECT in routine practice. Eur J Nucl Med Mol Imaging. 2023;50:1974–87.PubMedPubMedCentralCrossRef
85.
Ahlskog JE, Uitti RJ, O’Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease. Mov Disord. 1999;14:940–6.PubMedCrossRef
86.
Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999;14:436–42.PubMedCrossRef
87.
Fowler JS, Volkow ND, Logan J, Franceschi D, Wang GJ, MacGregor R, et al. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci. 2001;68:2759–68.PubMedCrossRef
88.
Group PS. Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression. JAMA. 2002;287:1653–61.CrossRef
89.
Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386:827–30.PubMedCrossRef
90.
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18:8417–22.PubMedPubMedCentralCrossRef
91.
Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206–14.PubMedCrossRef
92.
Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol. 2007;17:46–52.PubMedCrossRef
93.
Frankl JA, Bose S, Kuo PH. False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine. J Nucl Med Technol. 2018;46:149–50.PubMedCrossRef
94.
Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163:387–95.PubMedCrossRef
95.
Szobot CM, Shih MC, Schaefer T, Júnior N, Hoexter MQ, Fu YK, et al. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder–a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study. Neuroimage. 2008;40:1195–201.PubMedCrossRef
96.
Karila L, Leroy C, Dubol M, Trichard C, Mabondo A, Marill C, et al. Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [(11)C]-PE2I. Neuropsychopharmacology. 2016;41:2294–302.PubMedPubMedCentralCrossRef
97.
Spencer TJ, Madras BK, Bonab AA, Dougherty DD, Clarke A, Mirto T, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [11C]altropane and [11C]raclopride. Biol Psychiatry. 2010;68:964–70.PubMedCrossRef
98.
Lavalaye J, Linszen DH, Booij J, Dingemans PMAJ, Reneman L, Habraken JBA, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res. 2001;47:59–67.PubMedCrossRef
99.
Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology. 2007;191:805–11.PubMedCrossRef
100.
Alice P, Catriona I, Simon JGL. Visual Hallucinations and the Role of Medications in Parkinson’s Disease: Triggers, Pathophysiology, and Management. The Journal of Neuropsychiatry and Clinical Neurosciences. 2020;32:334–43.CrossRef
101.
Seo M, Oh M, Cho M, Chung SJ, Lee CS, Kim JS. The Effect of SSRIs on the Binding of (18)F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nucl Med Mol Imaging. 2014;48:287–94.PubMedPubMedCentralCrossRef
102.
Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages. J Neurol. 2007;254:185–90.PubMedCrossRef
103.
Yang Y, Cheon M, Kwak YT. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson’s Disease. Dement Neurocogn Disord. 2017;16:57–63.PubMedPubMedCentralCrossRef
104.
Chung M, Park YS, Kim JS, Kim YJ, Ma HI, Jang SJ, et al. Correlating Parkinson’s disease motor symptoms with three-dimensional [(18)F]FP-CIT PET. Jpn J Radiol. 2015;33:609–18.PubMedCrossRef
105.
Lee E, Lee JE, Yoo K, Hong JY, Oh J, Sunwoo MK, et al. Neural correlates of progressive reduction of bradykinesia in de novo Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:1376–81.PubMedCrossRef
106.
Lee MJ, Kim SL, Lyoo CH, Rinne JO, Lee MS. Impact of regional striatal dopaminergic function on kinematic parameters of Parkinson’s disease. J Neural Transm (Vienna). 2015;122:669–77.PubMedCrossRef
107.
Kim DH, Kyeong S, Cheon M, Ha SW, Yoo J, Kim SM. Characterization of idiopathic Parkinson’s disease subgroups using quantitative gait analysis and corresponding subregional striatal uptake visualized using (18)F-FP-CIT positron emission tomography. Gait Posture. 2020;82:167–73.PubMedCrossRef
108.
Lee R, Shin JH, Choi H, Kim HJ, Cheon GJ, Jeon B. Variability of FP-CIT PET Patterns Associated With Clinical Features of Multiple System Atrophy. Neurology. 2021;96:e1663–71.PubMedCrossRef
109.
Ryu HS, Oh M, Oh JS, Moon H, Park KW, Lee C, et al. Distinct clinical features of predominant pre-synaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy. J Neurol Sci. 2019;402:100–6.PubMedCrossRef
110.
Chung SJ, Lee S, Yoo HS, Lee YH, Lee HS, Choi Y, et al. Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson’s Disease. J Parkinsons Dis. 2020;10:1541–9.PubMedCrossRef
111.
Oh YS, Kim JS, Chung YA, You Ie R, Yang DW, Chung SW, et al. Orthostatic hypotension, non-dipping and striatal dopamine in Parkinson disease. Neurol Sci. 2013;34:557–60.PubMedCrossRef
112.
Shin HW, Chung SJ, Lee S, Cha J, Sohn YH, Yun M, et al. Dysautonomia is linked to striatal dopamine deficits and regional cerebral perfusion in early parkinson disease. Clin Nucl Med. 2020;45:e342–8.PubMedCrossRef
113.
Kwak IH, Lee YK, Ma HI, Lee S, Yun M, Kim YJ, et al. Striatal Subregion Analysis Associated with REM Sleep Behavior Disorder in Parkinson’s Disease. J Integr Neurosci. 2023;22:18.PubMedCrossRef
114.
Lee JY, Yoon EJ, Kim YK, Shin CW, Nam H, Jeong JM, et al. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. J Mov Disord. 2019;12:103–12.PubMedPubMedCentralCrossRef
115.
Shin C, Lee JY, Kim YK, Nam H, Yoon EJ, Shin SA, et al. Cognitive decline in association with hyposmia in idiopathic rapid eye movement sleep behavior disorder: a prospective 2-year follow-up study. Eur J Neurol. 2019;26:1417–20.PubMedCrossRef
116.
Oh YS, Kim JS, Hwang EJ, Lyoo CH. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:47–51.PubMedCrossRef
117.
Kim JH, Jeon J, Lee Y, Kim SM, Cheon M, Kim JY. Striatal Dopaminergic Loss and Dysphagia in Parkinson Disease. Clin Nucl Med. 2023;48:143–9.PubMedCrossRef
118.
Song IU, Kim YD, Cho HJ, Chung SW, Chung YA. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord. 2013;27:51–5.PubMedCrossRef
119.
Chung SJ, Yoo HS, Oh JS, Kim JS, Ye BS, Sohn YH, et al. Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease. Parkinsonism Relat Disord. 2018;51:43–8.PubMedCrossRef
120.
Oh YS, Yoo SW, Lyoo CH, Yoo JY, Yoon H, Ha S, et al. The Association of β-Amyloid with Cognition and Striatal Dopamine in Early. Non-Demented Parkinson’s Disease J Parkinsons Dis. 2021;11:605–13.PubMedCrossRef
121.
Park SB, Kwon KY, Lee JY, Im K, Sunwoo JS, Lee KB, et al. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson’s disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci. 2019;40:311–7.PubMedCrossRef
122.
Yoo HS, Lee S, Chung SJ, Lee YH, Lee PH, Sohn YH, et al. Dopaminergic depletion, beta-amyloid burden, and cognition in Lewy body disease. Ann Neurol. 2020;87:739–50.PubMedCrossRef
123.
Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage. 2004;21:1497–507.PubMedCrossRef
124.
Niethammer M, Tang CC, Ma Y, Mattis PJ, Ko JH, Dhawan V, et al. Parkinson’s disease cognitive network correlates with caudate dopamine. Neuroimage. 2013;78:204–9.PubMedCrossRef
125.
Kim H, Oh M, Oh JS, Moon H, Chung SJ, Lee CS, et al. Association of striatal dopaminergic neuronal integrity with cognitive dysfunction and cerebral cortical metabolism in Parkinson’s disease with mild cognitive impairment. Nucl Med Commun. 2019;40:1216–23.PubMedCrossRef
126.
Son HJ, Jeong YJ, Yoon HJ, Kim JW, Choi GE, Park JH, et al. Parkinson disease-related cortical and striatal cognitive patterns in dual time F-18 FP CIT: evidence for neural correlates between the caudate and the frontal lobe. Q J Nucl Med Mol Imaging. 2019;63:379–86.PubMedCrossRef
127.
Baik K, Cha J, Ham JH, Baek GM, Sunwoo MK, Hong JY, et al. Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson’s disease. Hum Brain Mapp. 2014;35:5431–41.PubMedPubMedCentralCrossRef
128.
Choi H, Cheon GJ, Kim HJ, Choi SH, Kim YI, Kang KW, et al. Gray matter correlates of dopaminergic degeneration in Parkinson’s disease: A hybrid PET/MR study using (18) F-FP-CIT. Hum Brain Mapp. 2016;37:1710–21.PubMedPubMedCentralCrossRef
129.
Chung SJ, Kim YJ, Kim YJ, Lee HS, Jeong SH, Hong JM, et al. Association Between White Matter Networks and the Pattern of Striatal Dopamine Depletion in Patients With Parkinson Disease. Neurology. 2022;99:E2672–82.PubMedCrossRef
130.
Fu Y, Zhou L, Li H, Hsiao JT, Li B, Tanglay O, et al. Adaptive structural changes in the motor cortex and white matter in Parkinson’s disease. Acta Neuropathol. 2022;144:861–79.PubMedPubMedCentralCrossRef
131.
Chung SJ, Kim YJ, Kim YJ, Lee HS, Yun M, Lee PH, et al. Potential Link Between Cognition and Motor Reserve in Patients With Parkinson’s Disease. J Mov Disord. 2022;15:249–57.PubMedPubMedCentralCrossRef
132.
Yoon HJ, Cho K, Kim WG, Jeong YJ, Jeong JE, Kang DY. Heterogeneity by global and textural feature analysis in F-18 FP-CIT brain PET images for diagnosis of Parkinson’s disease. Medicine (Baltimore). 2021;100: e26961.PubMedCrossRef
133.
Choi BW, Kang S, Kim HW, Kwon OD, Vu HD, Youn SW. Faster region-based convolutional neural network in the classification of different parkinsonism patterns of the striatum on maximum intensity projection images of [18 F]FP-CIT positron emission tomography. Diagnostics. 2021;11:1557.PubMedPubMedCentralCrossRef
134.
Hwang D, Kim KY, Kang SK, Seo S, Paeng JC, Lee DS, et al. Improving the accuracy of simultaneously reconstructed activity and attenuation maps using deep learning. J Nucl Med. 2018;59:1624–9.PubMedCrossRef
135.
Suh M, Im JH, Choi H, Kim HJ, Cheon GJ, Jeon B. Unsupervised clustering of dopamine transporter PET imaging discovers heterogeneity of parkinsonism. Hum Brain Mapp. 2020;41:4744–52.PubMedPubMedCentralCrossRef
136.
Park HK, Lim YM, Kim JS, Lee MC, Kim SM, Kim BJ, et al. Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism. J Neurol Sci. 2011;301:12–3.PubMedCrossRef
137.
Lim YM, Park HK, Kim JS, Lee CS, Chung SJ, Kim J, et al. Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome. Neurol Sci. 2013;34:875–81.PubMedCrossRef
138.
Chung EJ, Hwang JH, Lee MJ, Hong JH, Ji KH, Yoo WK, et al. Expansion of the clinicopathological and mutational spectrum of Perry syndrome. Parkinsonism Relat Disord. 2014;20:388–93.PubMedCrossRef
139.
Ryu HS, Hong CM. Brain F-18 FDG and F-18 FP-CIT PET/CT Findings of c.856_860delCTCTA Mutation McLeod Syndrome. Cogn Behav Neurol. 2021;34:207–11.PubMedCrossRef
140.
141.
Tang S, Dou X, Zhang Y. 18F-FP-CIT PET/CT in a case of probable sporadic Creutzfeldt-Jakob disease with parkinsonism as initial symptom. Prion. 2022;16:91–4.PubMedPubMedCentralCrossRef
142.
Lee K, Park DG, Kim MS, An YS, Yoon JH. Dual-Phase 18 F-FP-CIT PET in 2 Different Clinical Phenotypes of Sporadic Creutzfeldt-Jakob Disease. Clin Nucl Med. 2022;47:e548–9.PubMedCrossRef
143.
Kim YJ, Lyoo CH, Hong S, Kim NY, Lee MS. Neuroimaging studies and whole exome sequencing of PLA2G6-associated neurodegeneration in a family with intrafamilial phenotypic heterogeneity. Parkinsonism Relat Disord. 2015;21:402–6.PubMedCrossRef
144.
Kwon KY, Koh SB. A pilot study of F-18 FP-CIT PET imaging in early-onset patients with parkinson’s disease: parkin versus non-parkin mutation. Neuroquantology. 2018;16:52–6.CrossRef
145.
Kim JI, Choi JK, Lee JW, Kim J, Ki CS, Hong JY. A novel missense mutation in GCH1 gene in a Korean family with Segawa disease. Brain Dev. 2015;37:359–61.PubMedCrossRef
146.
Shin JH, Lee WW, Lee JY, Kim HJ, Jeon B. GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology. J Neurol. 2020;267:1952–9.PubMedCrossRef
147.
148.
Kim MS, Park DG, An YS, Yoon JH. Dual-phase (18) F-FP-CIT positron emission tomography and cardiac (123) I-MIBG scintigraphy of Parkinson’s disease patients with GBA mutations: evidence of the body-first type? Eur J Neurol. 2023;30:344–52.PubMedCrossRef
149.
Pak K, Seo S, Lee MJ, Im HJ, Kim K, Kim IJ. Limited power of dopamine transporter mRNA mapping for predicting dopamine transporter availability. Synapse. 2022;76: e22226.PubMedCrossRef
150.
Pak K, Seok JW, Nam HY, Seo S, Lee MJ, Kim K, et al. The association of DAT gene methylation with striatal DAT availability in healthy subjects. EJNMMI Res. 2021;11:58.PubMedPubMedCentralCrossRef
151.
Kwon KY, Koh SB. A pilot study of F-18 FP-cit pet imaging in early-onset patients with parkinson’s disease: Parkin versus non-parkin mutation. NeuroQuantology. 2018;16:52–6.CrossRef
152.
Xia Y, Jiang C, Cao Z, Shi K, Wang Y. Co-transplantation of macaque autologous Schwann cells and human embryonic nerve stem cells in treatment of macaque Parkinson’s disease. Asian Pac J Trop Med. 2012;5:7–14.PubMedCrossRef
153.
Im HJ, Hwang DW, Lee HK, Jang J, Lee S, Youn H, et al. In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease. Mol Imaging. 2013;12:224–34.PubMedCrossRef
154.
Jang W, Park J, Shin KJ, Kim JS, Kim JS, Youn J, et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson’s disease. J Neurol Sci. 2014;337:47–54.PubMedCrossRef
155.
Park BN, Kim JH, Lee K, Park SH, An YS. Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT. Eur Radiol. 2015;25:1487–96.PubMedCrossRef
156.
Oh SJ, Ahn H, Jung KH, Han SJ, Nam KR, Kang KJ, et al. Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson’s Animal Model. Mol Imaging Biol. 2020;22:1031–42.PubMedCrossRef
157.
Zhu Y, Tang X, Cheng Z, Dong Q, Ruan G. The anti-inflammatory effect of preventive intervention with ketogenic diet mediated by the histone acetylation of mGluR5 promotor region in rat parkinson’s disease model: a dual-tracer PET study. Parkinsons Dis. 2022;2022:3506213.PubMedPubMedCentral
158.
Lee SH, Kim M, Lee J, Kim JW, Kim MS, Jo S, et al. Clinical factors and dopamine transporter availability for the prediction of outcomes after globus pallidus deep brain stimulation in Parkinson’s disease. Sci Rep. 2022;12:16870.PubMedPubMedCentralCrossRef
159.
Yu KJ, Lee BJ, Han J, Park D. Usefulness of F-18 FP-CIT PET to predict dopamine-responsive hand tremor in patients other than Parkinson’s disease: Two case reports. Medicine (Baltimore). 2018;97: e10983.PubMedCrossRef
160.
161.
Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, et al. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Mov Disord. 2017;32:1482–6.PubMedPubMedCentralCrossRef
162.
Cooper CA, Chahine LM. Biomarkers in prodromal Parkinson disease: a qualitative review. J Int Neuropsychol Soc. 2016;22:956–67.PubMedCrossRef
163.
164.
Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, et al. Combination of “idiopathic” REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128:126–37.PubMedCrossRef
Metadata
Title
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET
Authors
Changhwan Sung
Seung Jun Oh
Jae Seung Kim
Publication date
17-01-2024
Publisher
Springer Nature Singapore
Published in
Nuclear Medicine and Molecular Imaging
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-024-00840-x